Home Molecular Dx Liquid Biopsies

Liquid Biopsies

Latest
Liquid Biopsies

Adela Raises $60M in Series A Financing Toward Liquid Biopsy, Starting...

Liquid Biopsies

Cancer Liquid Biopsy Developer Bluestar Raises $70M, Adds Venter to Scientific...

The Blood Profiling Atlas in Cancer Consortium (BloodPAC) has publicly released an initial dataset intended to help accelerate the development of liquid biopsy technology. [© Alex Tihonov/Fotolia]
Liquid Biopsies

NeoGeomics Splashes $390M to Buy Liquid Biopsy Developer Inivata

Biocept intends to become Thermo Fisher Scientific’s “Center of Excellence” for oncology-focused liquid biopsy efforts as part of a commercial collaboration by the companies. [© AlexRaths/iStock]
Liquid Biopsies

First “Tumor Uninformed” Cancer Recurrence Test Evaluated at Mass General

Genetic research, conceptual illustration
Liquid Biopsies

Agendia to Distribute Inivata’s RaDaR MRD and Cancer Recurrence LBx in...

illustration DNA And Blood cell Futuristic digital design,Abstract background for Business Science and technology
Liquid Biopsies

New Nanopore Technique Could Improve cfDNA Analysis

Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]
Liquid Biopsies

Novel Biomarker Could Aid Development of Drugs for Age-Related Disorders

Genetic research, conceptual illustration
Liquid Biopsies

Exact Sciences to Acquire Ashion Analytics from TGen

Inivata and Thermo Fisher Scientific are collaborating with Genomics England to assess the quality of blood plasma samples and explore the potential of liquid biopsy to improve disease management and patient outcomes. [Source: © Alex Tihonov/Fotolia]
Liquid Biopsies

Resolution Bioscience, Mirati Therapeutics Ink CDx Deal

The combination of Bristol-Myers Squibb (BMS)'s marketed cancer immunotherapies Opdivo (nivolumab) plus a low dose of Yervoy (ipilimumab) showed durable clinical benefit in a Phase II trial as a first-line treatment in patients with microsatellite instability-high (MSI-H) or DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
Liquid Biopsies

Guardant Throws Hat in Early Cancer Detection Ring with CRC Test

Load more

Featured

New Products

View More
Load more
Copyright © 2020 Genetic Engineering & Biotechnology News. All Rights Reserved.
Scroll Up